Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Sarepta shares fall 4% after FDA documents show safety concerns about drug

Stock MarketsJan 22, 2020 04:49PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Sarepta shares fall 4% after FDA documents show safety concerns about drug

By Carl O'Donnell

(Reuters) - Shares of Sarepta Therapeutics Inc (O:SRPT) were down around 4% Wednesday after the U.S. Food and Drug Administration revealed documents detailing concerns it had about the safety and efficacy of one of the company's recently approved Duchenne muscular dystrophy (DMD) drugs.

The drug, Vyondys 53, also known as golodirsen, was originally rejected by the FDA last year before the agency reversed that decision in December and approved it.

It was the second controversial drug approval for Sarepta. The company saw its first drug, Exondys 51, which also treats DMD, approved in 2016 despite concerns raised by experts about its effectiveness.

The newly released documents outlined concerns ranging from kidney toxicity, to infections, to low levels of effectiveness as reasons for the FDA's original rejection of the drug. The FDA cited some of these concerns at the time of its original rejection of Vyondys 53 but the documents provide further detail.

The documents added that Vyondys 53 comes with greater risk of kidney toxicity than Exondys 51 and that the risks of infection, which exist for both drugs, were not as well understood at the time Exondys was approved. Therefore, while Exondys was approved based on assumptions that it had "essentially no risk," Vyondys 53 has a less favorable risk profile.

"I have reached the conclusion that this small benefit, which has not yet been verified, does not outweigh its risks," Ellis Unger, a director at the Center for Drug Evaluation and Research, wrote in his letter.

Sarepta successfully appealed the FDA's decision in 2019. The company said it addressed the kidney toxicity issue in the drug’s label, which recommends monthly monitoring of patients.

The FDA said in a statement to Reuters that its eventual approval of Vyondys 53 demonstrates its flexibility in approving new drugs for serious diseases that have no satisfactory treatments available. It added that it stands by its eventual decision to approve the drug.

Both of Sarepta's drug approvals are contingent on it conducting additional post-marketing studies to show their efficacy and submitting them to the FDA.

(This story corrects typographical errors in paragraphs 5 and 8)

Sarepta shares fall 4% after FDA documents show safety concerns about drug
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email